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Abstract It has been more than two decades since the
original chromosome transmission fidelity (Ctf) screen of
Saccharomyces cerevisiae was published. Since that time
the spectrum of mutations known to cause Ctf and, more
generally, chromosome instability (CIN) has expanded dra-
matically as a result of systematic screens across yeast
mutant arrays. Here we describe a comprehensive summary
of the original Ctf genetic screen and the cloning of the
remaining complementation groups as efforts to expand our
knowledge of the CIN gene repertoire and its mutability in a
model eukaryote. At the time of the original screen, it was
impossible to predict either the genes and processes that
would be overrepresented in a pool of random mutants
displaying a Ctf phenotype or what the entire set of genes
potentially mutable to Ctf would be. We show that in a
collection of 136 randomly selected Ctf mutants, >65% of
mutants map to 13 genes, 12 of which are involved in sister
chromatid cohesion and/or kinetochore function. Extensive
screening of systematic mutant collections has shown
that ~350 genes with functions as diverse as RNA process-
ing and proteasomal activity mutate to cause a Ctf pheno-
type and at least 692 genes are required for faithful
chromosome segregation. The enrichment of random Ctf
alleles in only 13 of ~350 possible Ctf genes suggests that
these genes are more easily mutable to cause genome insta-
bility than the others. These observations inform our under-
standing of recurring CIN mutations in human cancers
where presumably random mutations are responsible for
initiating the frequently observed CIN phenotype of tumors.
Introduction
Genetic instability refers to circumstances that lead to alter-
ations of the genetic content of a cell. This instability can be
a regulated part of healthy cell growth, as in the case of
somatic hypermutability and developmentally controlled re-
arrangement of immunoglobulin genes (Upton et al. 2011).
Low level genetic instability in germ line cells is critical to
the evolutionary process as it generates variability within
species to support population adaptation to selective pres-
sures. Nonetheless, many outcomes of genetic instability
have a detrimental effect on the cell and/or the organism,
and hence knowing the etiology of genetic instability is
fundamental to understanding many human diseases. It has
long been known that aberrant chromosome number and
structure can cause developmental disorders such as Down
syndrome (Lejeune et al. 1959). The role of microsatellite
instability (MIN; increased mutation rate) and chromosomal
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opment is well documented (Lengauer et al. 1997), and the
identity of many cancer-causing somatic mutations is
known (e.g., Cancer Gene Census; Futreal et al. 2004).
Indeed, CIN is seen in the majority of human cancers and
is thought to play a role early in oncogenesis by creating a
mutational environment in which the necessary oncogenes
or tumor-suppressor genes are more likely to be mutated and
enable a malignant tumor phenotype (Stratton et al. 2009).
Analysis of genetic instability in model organisms has
proven to be highly relevant to the mechanistic understand-
ing of human genetic instability, as processes that control
genetic instability are well conserved. Greater than 60% of
baker’s yeast (Saccharomyces cerevisiae) genes are clearly
conserved across diverse organisms including humans
(Heinicke et al. 2007). Indeed, yeast has been instrumental
in delineating many of the pathways that protect the genome
from instability in large part due to its experimental acces-
sibility using genetic, cytological, and biochemical tools.
Genes identified several decades ago in screens for cell
division cycle control (CDC), mini-chromosome mainte-
nance (MCM), and mitotic spindle function were found to
be critical for maintaining genome integrity in yeast and
humans (Hartwell et al. 1970; Hoyt et al. 1990; Huffaker
et al. 1988; Maine et al. 1984). Additionally, early work in
yeast revealed much regarding the biology of important cis-
acting chromosomal features required for genome integrity
(e.g., centromeres, telomeres, autonomously replicating
sequences) (Chan and Tye 1980; Clarke and Carbon 1980;
Szostak and Blackburn 1982). Remarkably, recent work in
yeast has also shown that the state of aneuploidy alone is
sufficient to cause further genome instability and increased
mutation rates independent of the specific chromosomal
amplification (Sheltzer et al. 2011). Thus yeast genes, pro-
teins and genome architecture itself have contributed to our
understanding of eukaryotic genome integrity.
One of the first classical genetic screens whose sole
criterion was chromosome transmission was the chromo-
some transmission fidelity (Ctf) screen conducted in the
Hieter lab (Spencer et al. 1990). More recently, many groups
have exploited the yeast deletion collection for systematic
screens for defects in genome integrity by various criteria
(Andersen et al. 2008; Smith et al. 2004; Kanellis et al.
2007;Y u e ne ta l .2007). Efforts to screen for genome
instability phenotypes in genetically tractable model organ-
isms are ultimately aimed at revealing the spectrum of
mutability to CIN in a eukaryotic genome. Various factors
confound such a complete description, for example redun-
dancy of gene function may mask CIN phenotypes in strains
where only a single gene is mutated. Moreover, while non-
essential genes can be completely deleted for CIN studies,
essential genes must be tested as hypomorphic or condition-
al alleles that may exhibit allele-specific effects on genome
integrity. Furthermore, some genes tolerate a large spectrum
of individual missense mutations throughout the protein
sequence, while other genes do not (i.e., highly evolution-
arily conserved genes presumably do not tolerate mutations
well). In the face of these obstacles, it should be remem-
bered that the relevant CIN targets for human disease are the
pathways most likely to cause CIN while retaining cell
viability, if mutated at random.
Here we review the efforts to elucidate the yeast CIN
gene spectrum over the past two decades, particularly via
Ctf screening, using random and systematic approaches, and
describe successful examples of yeast CIN genes predicting
candidate human CIN genes in cancer (Spencer et al. 1990;
Yuen et al. 2007; Stirling et al. 2011; Barber et al. 2008). We
also describe the use of tiling microarrays to identify the two
remaining Ctf complementation groups CTF2 and CTF9 as
TOF1 and SMC3, respectively. The complete analysis of the
major targets of the Ctf screen provides a view of which
genes and pathways are the most mutable to a Ctf phenotype
by random mutational events in a model eukaryote.
Comprehensive screening of the yeast gene deletion and
essential mutant collections by loss of function or reduction
in function (i.e., direct tests of mutants for each gene)
provide a view of all genes whose mutation is sufficient to
cause a Ctf phenotype. By defining the genes most mutable
to Ctf at random and the identity of all possible Ctf genes,
we arrive at an important result. Only 13 of several hundred
possible Ctf genes account for 68% of the original Ctf
alleles found in multimember complementation groups.
Moreover, 12 of these 13 genes impact sister chromatid
cohesion and/or kinetochore function. This indicates dra-
matic differences in mutability of target Ctf genes and has
direct relevance to cancer where presumably random muta-
tions can initiate the oncogenic process.
Results and discussion
An early screen for highly mutable Ctf genes
The haploid phase of the budding yeast life cycle allows the
phenotypes of mutations to be revealed directly, without the
need to backcross for homozygosity. This makes mutagen-
esis screens for nonlethal phenotypes highly efficient. As
the loss of an endogenous chromosome from a haploid cell
would be a lethal event, a screen for chromosome loss
mutants required the design of a reporter strain containing
a nonessential artificial chromosome fragment. Spencer et
al. (1990) designed such a reporter to screen for mutants
with defects in chromosome transmission fidelity by inte-
grating a marker that would facilitate a visual colony color
assay. The screen took advantage of plasmids with several
important features to generate the reporter chromosome
264 Chromosoma (2012) 121:263–275fragment (Fig. 1a). Each plasmid contained a telomeric Y′
element separated from a unique chromosomal sequence by
a restriction site, a centromere, a selectable marker, and
SUP11. When linearized, the plasmid recombines to create
a partial disomy in which the telocentric chromosome frag-
ment contains one short, plasmid-derived arm with a yeast
telomere, and a long arm derived from yeast chromosomal
DNA (Fig. 1a; (Spencer et al. 1990). The Ctf assay relies on
the suppression of the ochre stop codon mutation in ade2-
101 by the SUP11 gene, which encodes a suppressing
tyrosyl-tRNA. While wild-type cells produce white colo-
nies, ade2-101 cells give rise to red colonies due to the
accumulation of an adenine precursor. The chromosome
fragment carrying SUP11 allows reading through the ade2-
Fig. 1 Features of the chromosome fragment and Ctf assay. a Sche-
matic of chromosome fragment construction as described in the main
text (Spencer et al. 1990). Briefly a plasmid with a unique restriction
between Y′ and unique sequences (inverted triangle) is digested and
used to transform a haploid strain. In this example, recombination
(indicated by large X) of the Y′ element (i) fuses the chromosome
fragment plasmid to the telomere on the right arm and coordinate
recombination of a unique pericentromeric site (ii) fuses the left arm
of the chromosome to the plasmid-telomere moiety to generate the
independent chromosome fragment (iii). Diagonal lines indicate large
chromosomal distances. b Schematic of the Ctf assay. ade2-101 cells
form red colonies (left) which are suppressed to a white color by
SUP11 (center). Mutagenesis of a Ctf gene leads to red sectors in a
white colony. The colony on the far right is half-sectored. The fre-
quency of half-sectored colonies, which are generated by loss of the CF
in the first cell division on the plate, can be used to quantify chromo-
some loss rates
Chromosoma (2012) 121:263–275 265101 mutation leading to an ADE2+ phenotype and suppres-
sion of the red color. Chromosome fragment-containing
strains with an increased rate of chromosome loss grow as
white colonies with red sectors derived from chromosome
fragment loss events when grown on medium containing
limiting adenine (for schematic see Fig. 1).
The visual Ctf assay system was the basis of the primary
screen involving ethyl methanesulfonate (EMS) mutagene-
sis of yeast cells. This screen was somewhat unique in that
the EMS concentration was reduced to permit ~100% cell
viability and a modest tenfold increase in mutations as
measured by de novo canavanine resistance (Spencer et al.
1990). Under these very light mutagenesis conditions, it
could be predicted that the Ctf mutants identified would
most likely be the result of mutations in single genes, thus
simplifying follow-up experiments. The original Ctf screen
yielded 136 Ctf mutants after screening ~600,000 indepen-
dent single colonies (Spencer et al. 1990). Of the 136 Ctf
mutants, 97 fell into 15 complementation groups ranging
from 2 to 30 alleles (CTF1-12 and CTF17-19), and 39 were
singletons. Subsequently, 26 Ctf genes, including represen-
tatives of all ≥2 member complementation groups and 11
singletons, were cloned either by complementation or, in
two cases, the array-based methods described below (Fig. 2
and Table 1). In total, 108 of 136 Ctf alleles are mapped to
mutations in these 26 cloned genes (Table 1).
Cloning of CTF2 and CTF9
The CTF2 and CTF9 allele groups remained uncloned follow-
ing repeated attempts to “clone by complementation” using
several yeast genomic libraries. A modern approach to identi-
fying the genes responsible for a mutant phenotype is to use
hybridization of mutant genomic DNA to microarrays consist-
ing of overlapping, short oligonucleotides tiled over the entire
yeast genome. Mismatches between the mutant genomic DNA
and the reference sequence from which the array was designed
lead to decreases in signal intensity at those probes.
Subsequent Sanger sequencing is required to determine the
nature of the base change. Of course, even more modern
technologies—namely, next-generation sequencing—have
also recently become economical ways to identify mutations.
Both methodscould prove usefulfor identifying the remaining
singletons from the Ctf screen, and the availability of these
techniques opens new possibilities for other genetic screens.
Tiling array analysis of genomic DNA from four CTF2
alleles and three CTF9 alleles identified single nucleotide
polymorphisms (SNP) in the TOF1 and SMC3 genes,
respectively (Fig. 2a, b). Each strain also contained
additional high probability SNP predictions outside of
TOF1 and SMC3. This was probably due to the use of
EMS to generate these mutations coupled with spontaneous
mutation accumulation during subsequent outgrowth and
strain manipulation. By using several alleles from each
complementation group, we were able to quickly identify
the causative mutations. TOF1 encodes a 141-kDa protein
that acts at stalled replication forks to promote chromatid
cohesion after DNA damage (Katou et al. 2003; Mayer et al.
2004). Smc3p is a structural subunit of the cohesin complex
and had a previously identified Ctf phenotype (Michaelis et
al. 1997; Haering et al. 2002). Sequencing of each CTF2
and CTF9 allele revealed premature stop codons in the
nonessential TOF1 gene and missense mutations in the
essential SMC3 gene (Fig. 2c, d). These mutations presum-
ably lead to complete or partial loss of function of TOF1,
consistent with the results of a systematic Ctf screen that
revealed a Ctf phenotype in tof1Δ cells (Yuen et al. 2007).
The SMC3 mutations are likely hypomorphic as loss of
function mutations in SMC3 would presumably be lethal.
We identified SMC3 S75N mutations in two ctf9 alleles.
Interestingly, SMC3 S75R mutations were found in a sup-
pressor screen for a mutant allele of the cohesin acetyltrans-
ferase ECO1 (Rowland et al. 2009). These data suggest that
SMC3 acetylation defects may play a role in the Ctf pheno-
type of these ctf9 alleles and highlights the importance of
this region of Smc3 to genome stability (Rowland et al.
2009). Together CTF2/TOF1 and CTF9/SMC3 accounted
for 14 of the original 136 Ctf alleles, completing analysis
of all multimember complementation groups (≥3 indepen-
dent alleles). The ability to clone most of the Ctf genes by
complementation indicated that recessive alleles were iden-
tified in all of the classified Ctf alleles. After mapping
CTF2/TOF1 and CTF9/SMC3 in this study (Fig. 2), only
singletons from the original Ctf screen remain uncloned.
Since most cloned Ctf alleles have been identified in other
assays and subsequent direct tests, most of the remaining
uncloned alleles have also likely been identified by subse-
quent studies of Ctf or other CIN phenotypes (Andersen et
al. 2008; Smith et al. 2004; Kanellis et al. 2007; Yuen et al.
2007; Stirling et al. 2011).
The original Ctf genes should represent those genes most
easily mutable to a Ctf phenotype because they were iden-
tified through a random screen. Table 1 lists the original Ctf
genes, the molecular function of the gene product, and
where known, the mutational status of the human ortholog
in tumors. The original Ctf screen identified some different
biological pathways but revealed a remarkable enrichment
for genes involved in sister chromatid cohesion and separa-
tion (e.g., with one exception, CDC6, all genes in multi-
member complementation groups are annotated as cohesion
or kinetochore related; Table 1). These include cohesin
subunits (SMC1, SMC3,a n dSCC3), a cohesin loader
(SCC2), kinetochore components (CHL3, MCM21, CTF13,
NDC10, CHL4, CTF19, and MCM16), and regulatory fac-
tors for these processes (i.e., cohesion: ECO1, PDS5,
RAD61,a n dCHL1, and kinetochore mitotic checkpoint:
266 Chromosoma (2012) 121:263–275MAD1). A presumably analogous situation exists in precan-
cerous cells where random mutations could lead to genome
instability. By identifying the Ctf genes that are the most
sensitive to random mutagenesis, we predicted that human
orthologs of the yeast Ctf genes may represent CIN genes
mutated in tumors. Subsequent studies of human tumors,
including candidate gene sequencing studies derived from
the yeast Ctf gene list, have identified human orthologs
Fig. 2 Genomic tiling array analysis of CTF2 and CTF9 alleles.
Prediction scores across the TOF1 (a) and SMC3 (b) open reading
frames in the composite of four CTF2 and three CTF9 alleles respec-
tively (“s” numbers indicate isolate number). A polymorphism in the
strain background (asterisk) is also visible in all CTF2/TOF1 alleles. c,
d Summary of sequencing data for TOF1 in 11 CTF2 alleles (c) and for
SMC3 in three CTF9 alleles (d). Normal protein sequence is schema-
tized as blue for Tof1p and orange for Smc3p.The amino acid number
and identity of each mutation is noted. Three TOF1 frameshift muta-
tions are indicated with additional amino acids schematized in red.
SMC3 point mutations are indicated in green
Chromosoma (2012) 121:263–275 267with mutations in 9 of the 18 original Ctf genes (see
Table 1 and below).
Secondary screening: Ctf as an entry point to chromosome
biology
Subsequent to the original screen, other groups have used
the Ctf assay as a starting point to characterize specific
biological pathways. An elegant example of this approach
identified the cohesin complex (Michaelis et al. 1997). The
authors engineered a Ctf assay strain in which the essential
anaphase-promoting complex subunit CDC16 was mutated
to allow conditional cell cycle arrest at anaphase. They
mutagenized their reporter strain with EMS to 40–60%
survival, a considerably heavier mutagenesis than the orig-
inal Ctf screen (Spencer et al. 1990) and identified 377 Ctf
alleles. The CDC16 ts allele enabled them to arrest each Ctf
mutant at anaphase via temperature shift and to visually
screen for the ability of the mutants to separate their nuclei
and elongate their spindles (Michaelis et al. 1997). This
directed secondary screen identified four complementation
groups corresponding to the cohesin genes SMC1, SMC3,
and SCC1 and the cohesin loader SCC2. By engineering a
secondary screening tool into their Ctf screen, the authors
were able to illuminate an important biological process.
Secondary screens have been used repeatedly to assign
functions to Ctf mutants in the past two decades. For exam-
ple, monitoring the integrity of kinetochores in the Ctf
mutant collection identified two of the first kinetochore
proteins, Ctf13 and Ctf14/Ndc10 (Doheny et al. 1993).
This development was followed by the discovery of roles
for Spt4 and nucleoporins in kinetochore function using the
same secondary assay (Basrai et al. 1996; Iouk et al. 2002;
Kerscher et al. 2001). Subsequent development of the
Table 1 Cloned Ctf genes from the original screen (Spencer et al. 1990)
Ctf name # alleles Alternate name Function or cellular complex Essentiality Human ortholog Mutated in cancer (data source or
“unknown” is indicated)
CTF1 30 CHL1 Cohesion Nonessential DDX11 COSMIC (Forbes et al. 2010)
CTF2 11 TOF1 Cohesion/DNA replication Nonessential TIMELESS COSMIC
CTF3 11 CHL3 Outer kinetochore Nonessential CENPI COSMIC
CTF4 8 POB1 Cohesion/DNA replication Nonessential WDHD1 Unknown
CTF5 5 MCM21 Outer kinetochore Nonessential – N/A
CTF6 5 RAD61 Cohesion Nonessential WAPL COSMIC & Oikawa et al. 2004
CTF7 5 ECO1 Cohesion Essential ESCO1 Unknown
CTF8 3 CTF8 Cohesion/alternative RFC Nonessential CHTF8 Unknown
CTF9 3 SMC3 Cohesion Essential SMC3 (Barber et al. 2008)
CTF10 3 CDC6 DNA Replication Essential CDC6 COSMIC
CTF11 3 PDS5 Cohesion Essential PDS5A/B Unknown
CTF12 3 SCC2 Cohesion Essential NIPBL (Barber et al. 2008)
CTF13 1 CTF13 Inner kinetochore Essential – N/A
CTF14 1 CBF2 Inner kinetochore Essential – N/A
CTF15 1 RPB4 RNA polymerase II subunit Essential POLR2D Unknown
CTF17 2 CHL4 Outer kinetochore Nonessential – N/A
CTF18 3 CTF18 Cohesion/alternative RFC Nonessential CHTF18 COSMIC
CTF19 2 CTF19 Outer kinetochore Nonessential – N/A
s3 1 BIM1 Distal microtubule/cohesion Nonessential MAPRE1 Unknown
s127 1 SIC1 Cell cycle regulator Nonessential – N/A
s138 1 SPT4 Chromatin/transcription/kinetochore Nonessential SUPT4H1 Unknown
s141 1 NUP170 Nucleoporin/kinetochore/checkpoint Nonessential NUP155 COSMIC
s143 1 MAD1 Outer kinetochore/checkpoint Nonessential MAD1L1 COSMIC
s155 1 MCM16 Outer kinetochore Nonessential – N/A
s165 1 SCC3 Cohesion Essential STAG3 (Barber et al. 2008)
s166 1 SMC1 Cohesion Essential SMC1A (Barber et al. 2008)
Notes: CTF1-16 was identified in Spencer et al. 1990; CTF16 remains an uncloned singleton. Multiple alleles of CTF17–19 were isolated in
secondary screens of the Ctf collection which resulted in their naming as “CTF” genes and, combined with CTF1–12, totals 97 alleles in greater
than two-member complementation groups. Eleven singletons are cloned (CTF13–15 and s3–s166) and bring the total to 26 cloned Ctf genes.
Therefore, 108 of 136 original Ctf alleles map to mutations in these 26 cloned genes and 28 singletons remain uncloned
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used to identify other kinetochore proteins including Ctf19p
and Ctf3p (Hyland et al. 1999; Measday et al. 2002). More
recently, a small-scale survey of telomere length in unchar-
acterized essential CIN and Ctf mutants led to the functional
characterization of the yeast TTT (Tel2-Tti1-Tti2) complex,
which has a conserved role in the biogenesis of phosphatidyl
inositol 3-kinase-related kinases (Stirling et al. 2011; Hurov
et al. 2010; Takai et al. 2010). In each case the choice of
secondary assay determined the functions discovered for the
Ctf genes. As the number of Ctf and CIN genes expands, it
is increasingly clear that there are many mechanisms that
stabilize the genome. In this light, choosing an appropriate
secondary assay is critical to delineating the pathways that
lead to genome instability in a particular mutant background.
Systematic screening for Ctf mutants in ordered
mutant arrays
The development of the systematic yeast deletion collection
and the synthetic genetic array technology made possible
the systematic screening of single yeast gene deletions for
Ctf phenotypes (Tong et al. 2001; Winzeler et al. 1999).
These genome scale “reverse” genetic approaches provide
the opportunity to answer the question “what are all genes
mutable to Ctf in yeast?” This approach has several advan-
tages over random mutagenesis, primarily the high coverage
rate that comes with the ability to directly test an individual
null mutant and knowledge of the gene deletion being
tested, which removes the need for subsequent cloning steps
(although it is still advisable to confirm the deletion is
causing your phenotype of interest). In addition, direct com-
parison of Ctf chromosome loss rates can be informative
when complete null alleles are tested as opposed to compar-
isons of different hypomorphic alleles. However, screening
the systematic gene deletion array does remove the potential
of finding dominant or neomorphic alleles. Such a screen
also erases any information on which genes are the most
easily mutable to the Ctf phenotype and does not interrogate
essential genes.
A systematic Ctf screen of nonessential gene deletions
was published in 2007 and identified 89 deletion mutants
with detectable Ctf phenotypes (Yuen et al. 2007). More
recently, it has become possible to test hypomorphic or
temperature-sensitive alleles of essential genes systematical-
ly (Ben-Aroya et al. 2008; Breslow et al. 2008; Li et al.
2011). The spectrum of essential Ctf genes has also been
expanded by testing ~2,000 alleles of more than 1,000
essential genes (Stirling et al. 2011). When combined with
previous work, this study identified a list of 354 mutants
with Ctf phenotypes, comprising 237 essential and 117
nonessential genes (Yuen et al. 2007; Stirling et al. 2011;
Measday et al. 2005). The large proportional excess of
essential Ctf genes may reflect the critical nature of faithful
chromosome segregation. The essential Ctf genes are in-
volved in a small number of cellular processes and often
encode proteins that function in complexes with many sub-
units; for example, the kinetochore, the replication appara-
tus, the proteasome, and the general transcription machinery
together account for a large percentage of the Ctf genes and
each is composed of many essential subunits. Together these
systematic Ctf screens should have identified the large ma-
jority of single genes mutable to a Ctf phenotype. One
implication of this hypothesis is the ability to confidently
ascribe Ctf mutability to entire cellular pathways. This
approach gains even more power when combined with the
various other CIN phenotypic screens that have been con-
ducted on a genome-wide scale (Fig. 3; Stirling et al. 2011).
Evaluation of diverse CIN phenotypes reveals
common themes
Systematic screening for CIN phenotypes in yeast has been
conducted using at least four other assays in addition to Ctf:
namely, haploid a-like faker (ALF), diploid bi-mater (BiM),
diploid loss of heterozygosity (LOH), and haploid gross
chromosomal rearrangements (GCR) (Andersen et al.
2008; Smith et al. 2004; Kanellis et al. 2007; Yuen et al.
2007). The ALF and BiM assays measure loss of an endog-
enous locus (MAT) in haploid MATα or diploid MATa/
MATα cells, respectively (Haber 1974; Yuen et al. 2007).
LOH measures nonconservative rearrangements within or
between homologous chromosomes that lead to hemi- or
homozygosity of the met15Δ locus starting from a met15Δ/
MET15 heterozygous diploid (Andersen et al. 2008). The
GCR assay measures loss of a distal portion of a chromo-
some arm, typically by terminal deletion and de novo telo-
mere addition (Smith et al. 2004; Kanellis et al. 2007). Each
assay reports on loss of a genetic marker that can originate
from several possible mechanisms. Thus, the CIN gene lists
from each phenotypic screen are only partially overlapping
(Yuen et al. 2007; Stirling et al. 2011). The aggregate output
of the various CIN screens creates an organism-wide view
of cellular structures and pathways comprising 692 genes
that ensure the faithful transmission of the genome to sub-
sequent generations.
Perhaps unsurprisingly, analysis of CIN genes en masse
indicates that typical CIN genes encode nuclear proteins
with functions closely linked to DNA or mitosis (Stirling
et al. 2011). However, the compilation of CIN genes does
identify >100 genes with peripheral or poorly understood
functions in genome integrity, and for many of these path-
ways the mechanism of CIN is not clear (Fig. 3). A mech-
anistic understanding of CIN in each mutant is not currently
available; however, in many cases a simple hypothesis can
be generated to explain the role of a particular cellular
Chromosoma (2012) 121:263–275 269pathway implicated in genome integrity. This is because
each CIN mutation must ultimately cause or fail to correct
one of only a few cellular events (i.e., DNA damage/DNA
repair or chromosome non-disjunction). For example, >100
CIN gene products function directly in either DNA replica-
tion or DNA repair and it is rational to hypothesize that CIN
arises due to faulty replication or repair of endogenous DNA
damage (Stirling et al. 2011; Lange et al. 2011). Similarly,
the ~70 CIN genes involved in kinetochore and spindle
function could lead to aneuploidy as a result of mitotic
defects and chromosome non-disjunction (Stirling et al.
2011; Thompson et al. 2010). In addition, many seemingly
peripheral CIN pathways have been mechanistically linked
to canonical genome stability pathways (i.e., the nuclear
pore and proteasome function directly in DNA repair
(Kerscher et al. 2001; Nagai et al. 2008; Ben-Aroya et al.
2010)). Another large class of CIN genes pertains to the
production of RNA, either at the level of transcription or
RNA processing including mRNA, tRNA, and rRNA
(Stirling et al. 2011). Multiple hypotheses on the role of
RNA production or processing and its interplay with ge-
nome stability have been put forward and differ depending
on the mutant in question. Transcription can lead to genome
instability through collision with DNA replication forks
(Sikdar et al. 2008; Prado and Aguilera 2005; Takeuchi et
al. 2003) but the transcriptional apparatus also plays a direct
role in DNA repair (i.e., transcription-coupled repair;
reviewed by Hanawalt and Spivak 2008). Splicing of a
single transcript, alpha tubulin (TUB1), has been shown to
affect genome stability due to dysregulated α/β-tubulin
levels and subsequent mitotic spindle defects (Biggins et
al. 2001;B u r n se ta l .2002). Finally, mRNA processing
defects can also cause genome instability through the pro-
duction of R-loops, which are RNA:DNA hybrids normally
removed co-transcriptionally by processing and export fac-
tors (PCS, PH, and Yujia A. Chan, unpublished observation;
D. Koshland personal communication; Gomez-Gonzalez et
al. 2009; Mischo et al. 2011). Thus, even seemingly related
CIN genes (e.g., spliceosome and mRNA processing) could
have different mechanisms leading to CIN that require direct
experimental validation.
Mutability and the value of classical screens
Systematic analysis has revealed the spectrum of genes that
are potentially mutable to a Ctf phenotype but gives no
information on the relative mutability of individual genes
or pathways. In the case of deletions, direct tests give a
“yes” or “no” answer, whereas hypomorphic alleles of es-
sential genes provide a “yes” or “probably not” answer
because allele specificity and incomplete loss of function
cannot eliminate the possibility that other alleles may show
Ctf. While the strength of phenotypes may provide some
information regarding the importance of individual genes or
pathways to chromosome segregation, systematic screens
cannot answer which genes are the most highly mutable to
Ctf. Naively, one might think that nonessential genes would
be more mutable since they are dispensable for viability.
However, the frequency of Ctf alleles in nonessential genes
is similar to the frequency of nonessential genes in the
yeast genome (~80% in each case; Table 1), suggesting
that no such bias exists. The cloning of CTF2 and CTF9
Fig. 3 A network of CIN-associated gene ontology terms. GO terms
associated with ≥20 CIN genes were included and then filtered for
redundant terms to retain the most genes while simplifying the net-
work. Node size is set to number of genes annotated to a term and edge
weight is set to the number of genes overlapping between terms. The
figure encompasses >80% of the 692 CIN genes reported (Stirling et al.
2011). Blue node color indicates ≥2 genes from the 13 multimember
Ctf complementation groups from Spencer et al. (1990)( CTF1–
CTF12, CTF18) are annotated to that GO term. Darker blue indicates
more genes annotated to that term (i.e., establishment of/mitotic sister
chromatid cohesion—12 genes; DNA replication—6 genes; DNA re-
pair, meiosis—4 genes; mitosis—3 genes; chromosome, replication
fork protection complex, kinetochore—2 genes)
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essential versus nonessential genes; all of the CTF2/TOF1
mutants are truncations, whereas only point mutations are
found in the essential CTF9/SMC3 gene (Fig. 2). Prior
studies have demonstrated the wide variation in mutability
of specific genes in random mutation collections. For ex-
ample, extensive CDC screening did not identify mutations
in β-tubulin (TUB2), whereas subsequent direct mutagene-
sis of the cloned TUB2 gene, and introduction into the yeast
genome, led to the identification of tub2-ts alleles that cause
a CDC phenotype (Hartwell et al. 1970; Huffaker et al.
1988). TUB2 is clearly mutable to a CDC phenotype when
directly tested but evidently dozens of other genes are more
mutable (Hartwell et al. 1973). The most important factors
controlling the relative mutability of genes to a phenotype
are poorly understood.
Our data suggest striking differences in mutability within
the Ctf genes—if the 354 Ctf genes were equally mutable
the probability of finding three alleles of the same gene from
the 136 original Ctf alleles would be P00.0069, yet more
than two thirds of the original Ctf alleles are accounted for
by 13 genes in complementation groups with greater than or
equal to three members (Table 1). Clearly, the structural
elements of a gene (e.g., size, genomic position, number of
codons mutable to stop by single base substitutions, etc.
discussed in Lang and Murray 2008) influence its mutabil-
ity, in addition to the effect of the gene’s impact on cellular
fitness and the strength of the relevant phenotype. The
question of mutability to a phenotype in a pool of variants
is particularly relevant to Ctf/CIN phenotypes because of
their functional relationship to oncogenesis, where a pre-
sumably random mutation initiates a CIN phenotype. The
original screen for Ctf clearly pointed to cohesion as the
most mutable process including mutations in the cohesin
subunits themselves (Table 1; Spencer et al. 1990).
Subsequent work has suggested that chromatid cohesion is
critical to preventing CIN in cancer and that cohesin sub-
units are mutated in colorectal tumors (Barber et al. 2008;
Schvartzman et al. 2010; Xu et al. 2011). A recent study has
demonstrated that a mutation in a cohesin subunit in
human cancer causes aneuploidy (Solomon et al. 2011).
Because of obvious advantages (i.e., coverage, mutant
identification), most genetic screens are now done on a
systematic basis using arrayed or pooled collections of
known mutants. However, with the proliferation of next-
generation sequencing, the ability of classical screens to
detect the most labile genes in a phenotypic assay could
be revisited as an alternative to systematic screens in
certain circumstances. Perhaps most importantly, the
issue of mutability impacts human cancers, where recur-
ring mutations of particular CIN genes are probably due
both to selection and preferential mutability of certain
targets.
Implications for CIN in human health and disease
Driver mutations in cancer can be subdivided into two broad
classes: oncogenes (i.e., gain of function mutations that
induce proliferative and/or survival phenotypes) and tumor
suppressors (i.e., loss of function mutations in genes whose
normal function counteracts proliferative and survival sig-
nals). CIN mutations could be considered a third class or
perhaps as a subcategory of tumor suppressors. CIN typi-
cally arises from the loss of function of a gene that protects
genome integrity, similar to the protective effects of tumor
suppressors. However, genetic instability itself is insuffi-
cient to drive tumor formation; rather it creates an environ-
ment in which the mutations, translocations, or copy number
alterations needed for a proliferative cancer phenotype are
more likely to occur (Stratton et al. 2009; Schvartzman et al.
2010; Cahill et al. 1999). A possible role for CIN or mutator
mutations as early events in tumorigenesis is illustrated in
Fig. 4 (similar concepts are portrayed in Stratton et al. 2009;
Loeb 2011). Somatic cells are exposed both to the perils of
normal mitosis and to potentially mutagenic environmental
factors. At some frequency, this mutational pressure will
randomly mutate a CIN gene, which in turn dramatically
increases the rate of mutations/chromosomal abnormalities
in subsequent mitoses (Fig. 4). Ultimately, oncogenic
mutations are selected from a mutated population. Recent
research has confirmed, at least in a childhood acute lym-
phoblastic leukemia, that tumor cell populations have var-
iegated genetic content and follow complex and nonlinear
evolutionary paths (Anderson et al. 2011). The genetic
variation created by CIN or MIN mutations within a tumor
population could also facilitate adaptation to the stresses
intrinsic to tumor growth (e.g., apoptotic signals, hypoxia,
and nutrient restriction) and extrinsic pressures such as
chemotherapy or radiation (Anderson et al. 2011;P a v e l k a
et al. 2010).
One approach to utilize yeast Ctf genes to identify cancer
genes has been candidate gene sequencing. One such study
sequenced the homologs of 96 yeast CIN genes in a colo-
rectal tumor sample and found 11 genes with somatic muta-
tions, 4 in cohesin subunits (Barber et al. 2008).
Resequencing a panel of colorectal tumors determined that
several cohesin subunits are mutated in ~3% of tumors and
thus together may underlie a significant proportion of colo-
rectal tumors (Barber et al. 2008). An earlier study used
genome instability phenotypes in both yeast and Drosophila
to identify human candidate CIN genes for sequencing
(Wang et al. 2004). With the emergence of next-generation
sequencing, the days of candidate gene sequencing may be
limited. Instead, researchers will opt to sequence the ge-
nome of a tumor and matched normal tissue to identify all
possible somatic mutations. This has already led to an
abundance of data regarding somatic variants with limited
Chromosoma (2012) 121:263–275 271phenotypic information for most of them. For example, at
the time of writing, the COSMIC database contained records
of >550 whole cancer genomes and >200,000 mutations
(http://www.sanger.ac.uk/genetics/CGP/cosmic/) (Forbes et
al. 2010). Presumably, most of the mutations in a tumor are
“passenger” mutations that do not contribute significantly to
the disease phenotype. It is our opinion that model organ-
isms can contribute to the dissection of the functions of
these somatic variants. This viewpoint spurred our recent
effort to catalog CIN phenotypes in essential yeast genes
and compile a master list of CIN pathways (Stirling et al.
2011). The phenotypic blueprints provided by systematic
screens in model organisms can help guide the search for
functional variants among tumor somatic mutations. In other
words, we predict that a candidate gene for CIN in a tumor
will typically belong to a cellular pathway known to cause
CIN in model organisms. Thus, having high-quality surveys
of tumor-relevant phenotypes in model organisms should
create a functional filter for somatic variants in tumors (i.e.,
Table 1; Stirling et al. 2011).
Understanding the spectrum of CIN genes will allow us
to understand the etiology of human diseases associated
with genetic instability and ultimately help design strategies
to combat these diseases. One powerful approach to design-
er therapeutics that has gained significant attention in recent
years is to exploit the concept of synthetic lethality. (For a
recent review see Brough et al. 2011). Synthetic lethality
describes a situation where two viable single mutations lead
to cell death when they occur in the same cell/organism. The
application of this concept to cancer was first articulated
nearly 15 years ago by Hartwell et al. (1997). Since cancers
are genetically distinct from surrounding tissues, there exists
an opportunity to leverage synthetic genetic interactions to
selectively kill tumors based on the very genetic differences
that permit oncogenesis. In principle, synthetic lethality can
target oncogenes or tumor suppressors, and there are now
numerous large-scale efforts to define genetic interactions
both in human cancer cells and in model organisms (e.g.,
Costanzo et al. 2010, Luo et al. 2009). Since CIN pheno-
types are common to diverse tumors, we suggest that syn-
thetic lethal targeting of CIN mutations is a viable
therapeutic approach. In fact, we have already exploited
conserved genetic interactions from yeast to identify con-
ditions that selectively kill CIN gene-deficient tumor cells
(McManus et al. 2009). Accordingly, the synthetic lethal
partners of the most highly mutable human cancer CIN
genes would be predicted to be the best and broadest ther-
apeutic targets. The combination of tumor genome sequence
data and mutant identification with genetic interaction net-
works and insights into relative mutability should continue
to present novel therapeutic opportunities in the future.
Ctf in the next two decades
With the advent of next-generation sequencing, human tu-
mor genome sequencing data are currently leading to the
identification of a huge number of variants with potential
relevance to cancer. Determining which of these variants is
responsible for the CIN phenotype seen in various tumors is
a challenge and a daunting task for biologists. One future
direction that yeast Ctf and, more broadly, CIN phenotypes
will play a role is in predicting functionality for human CIN
Fig. 4 Possible role of CIN in human tumors. CIN mutations may
facilitate the evolutionary process underlying tumorigenesis. This con-
cept is also illustrated for mutator phenotypes in the literature (Stratton
et al. 2009;L o e b2011). From left to right, a cellular mutational
pathway is fed by intrinsic and extrinsic factors and can lead to a
CIN mutation (blue diamond). CIN creates a mutant population in
which oncogenic mutations driving proliferation are more likely to
occur (red star). The proliferative phenotype and increased CIN facil-
itate variation (green star) that can help tumors respond to the envi-
ronmental challenges (e.g., hypoxia, chemotherapy)
272 Chromosoma (2012) 121:263–275candidate genes mutated in tumors. Given the considerable
evolutionary distance between yeast and humans, it is likely
that other model systems will contribute to this effort as
technologies improve. We predict that model organisms will
continue to directly contribute to efficient functional analy-
sis of tumor-associated somatic variants. For example, yeast
has proven to be a useful system to test the function of a
complementing human cDNA or assess the function of
conserved residues in human disease proteins (e.g., Gammie
et al. 2007, Jeong et al. 2007,M a r i n ie ta l .2008). In principle
these complementation or homology-based approaches could
be applied to assess the role of human tumor variants in
genome integrity.
One approach that will be used more widely in the future
is screening cultured mammalian cells using genome-wide
siRNA or shRNA libraries. While a screen for increased
aneuploidy in siRNA/shRNA-treated cells has yet to be
published, there have been several relevant screens con-
ducted. For example, mammalian genome-wide screens for
increased sensitivity to ionizing radiation or spontaneous γ-
H2Ax phosphorylation have been conducted (Hurov et al.
2010; Paulsen et al. 2009). The expense and lack of facile
genetics make an RNAi screening approach in tissue culture
impractical for many labs and highlight the importance of
model organisms for biological validation. However,
screening of CIN and other phenotypes in high throughput
directly in human cells has obvious advantages and imme-
diate relevance to human disease. Indeed, efforts by the
MitoCheck consortium have generated impressive datasets
of physical interactions within the mammalian chromosome
segregation pathway and siRNAs that induce various
mitotic defects in human cells (Hutchins et al. 2010;
Neumann et al. 2010). These datasets have already impli-
cated many new proteins in chromosome segregation and
will certainly have an impact on our understanding of CIN
in cancer.
The rate of genome instability should itself be a trait
subject to variation among individuals. Certainly, the study
of genome instability in model organisms demonstrates
that a highly significant variation in this trait is compatible
with viability. Interestingly, early documentation of varia-
tion in mutation rate among humans has been recently
revealed in whole genome sequence analysis of family
trios (the 1000 Genomes Project et al. 2011). How variable
is the CIN rate among individuals in the current human
population? Which pathways contribute most strongly to
natural variation in CIN, for humans or for organisms
occupying other niches? The past two decades have eluci-
dated many, if not most, of the players. Perhaps the next
two decades will translate the Ctf data to therapeutic use in
humans and reveal how cells and organisms both preserve
and enrich their genomic repertoires in the context of
ongoing evolution.
Materials and methods
Comparative genome hybridization
Four CTF2 (s1, s29, s38, and s59) and three CTF9 (s16, s24,
and s104) alleles were chosen from the original Ctf mutant
collection (Spencer et al. 1990). DNA preparation, micro-
array hybridization, and data analysis were performed as
described (Gresham et al. 2006).
Sequencing of TOF1 and SMC3
TOF1 from 11 CTF2 alleles and SMC3 from 3 CTF9 alleles
were amplified using Platinum PCR SuperMix High
Fidelity (Invitrogen #12532-016) according to the manufac-
turer’s instructions with primers flanking the gene of inter-
est. Sequencing was performed by Retrogen using 5-ng/uL
template DNA and 100-pmol primer. Primers for sequenc-
ing included regions 100–150 bp upstream and downstream
of the ORF. Where tiling microarray hybridization was
employed, the base pair changes matched closely with the
chromosomal coordinates of the predicted SNP (Fig. 2).
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